Technical, Preclinical, and Clinical Developments of Fc Glycan-Specific Antibody-drug Conjugates

Fc-glycan-specific ADC is a significant advance in site-specific ADCs for cancer therapy. Notably, JSKN003 and IBI343 have demonstrated promising results in phase 1 clinical trials and are advancing into phase 3 studies.